Partial
Partially Aligned
Patient Risk:
Low
Summary
The response accurately identifies ISENTRESS as containing raltegravir and as an antiretroviral based on the label's description of raltegravir as an HIV integrase strand transfer inhibitor. However, the label does not support the claims about branded status, 2023 generic competition, or effects on brand revenue.
Category Scores
Accurate Statements
Isentress is an antiretroviral drug.
Section 11 identifies ISENTRESS as containing raltegravir, a human immunodeficiency virus integrase strand transfer inhibitor, supporting its antiretroviral characterization.
Isentress is raltegravir.
Section 11 states that ISENTRESS contains raltegravir potassium and describes raltegravir content in its dosage forms. The statement is broadly accurate but imprecise because the product contains raltegravir rather than being identical to the active ingredient alone.
Unsupported Statements
Isentress is a branded antiretroviral drug.
The supplied label supports the antiretroviral characterization but does not state that ISENTRESS is a branded product.
In 2023, Isentress typically faced generic competition in multiple markets.
The supplied label contains no information about generic competition, markets, or events in 2023.
Generic competition often lowers brand revenue compared with earlier years.
The supplied label contains no information about generic competition, brand revenue, or revenue trends.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims do not address dosing, contraindications, warnings, interactions, administration, or other treatment-safety issues. The unsupported statements concern commercial and market information rather than direct patient management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Three claims extend beyond the supplied label, including branded status, 2023 generic competition, and revenue effects.
Suggested Improvement
Limit the description to the label-supported statement that ISENTRESS contains raltegravir potassium, an HIV integrase strand transfer inhibitor, and clearly identify commercial claims as outside the supplied prescribing information.